Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 June 2023 | Story André Damons | Photo Sonia Small
Prof Carolina Pohl-Albertyn
Prof Carlien Pohl-Albertyn, National Research Forum (NRF) SARChI Research Chair in Pathogenic Yeasts, leads the research team that is working on various research projects relating to fungi casing yeast.

Fungal infections affect more than one billion people each year, of which more than 150 million cases are severe and life-threatening, causing 1.7 million deaths a year. In South Africa it is estimated that diseases caused by fungal infections total more than three million cases a year. These figures are especially shocking given that prior to 1980, fungal infections were not a major health problem. The WHO has recently published a list of priority pathogens in which fungi are classified in critical, high- and medium- priority groups. Candida species are found in all three levels and Cryptococcus species in critical and medium groups,” says Prof Pohl-Albertyn.

It is for these reasons that researchers in the Department of Microbiology and Biochemistry at the University of the Free State (UFS) are working on various research projects investigating new treatment options beyond the established antifungals. Prof Carlien Pohl-Albertyn, National Research Forum (NRF) SARChI Research Chair in Pathogenic Yeasts, leads the team that is working on various research projects relating to fungi casing yeast.

Multidrug-resistant yeast

One of the yeasts being researched is Candida auris – a multidrug-resistant yeast that can cause severe infections in humans, particularly in people who are hospitalised or have weakened immune systems. C. auris was first identified in 2009 in Japan and has since been reported in over 49 countries.

According to Prof Pohl-Albertyn, C. auris is of concern because it is often resistant to multiple antifungal drugs, making it difficult to treat. In addition, it can survive on surfaces in healthcare settings, which can contribute to its spread between patients, causing outbreaks in hospitals. “Due to its multidrug resistance and potential for transmission, C. auris has been designated by the Centers for Disease Control and Prevention (CDC) as a serious global health threat and listed as the second most critical fungal pathogen in the World Health Organisation (WHO) fungal critical priority group.

C. auris possesses virulence factors such as increased thermotolerance, high salinity tolerance, biofilm formation, and extra cellular enzyme secretion, which are the major contributing factors to its multidrug resistance profile and virulence. Even though C. auris has a variety of virulence factors that it employs against its human host to develop an infection, its virulence mechanisms remain unclear,” says Prof Pohl-Albertyn.

Therefore, several research projects investigate this pathogenic yeast. All of them started with the development of CRISP-Cas9 gene editing tools for this yeast, in order to be able to delete specific genes in this yeast to study their roles. These tools are also constantly being improved for greater efficiency by students under the supervision of Prof Koos Albertyn. Two current projects deal with the function of specific secreted enzymes in the virulence of C. auris.

Environmental yeast

Another yeast being researched, under the supervision of Prof Olihile Sebolai, is Cryptococcus neoformans, an environmental yeast found in trees and soil contaminated with bird droppings. Moreover, it can be airborne and when inhaled it lodges in the lungs (in alveoli) and can cause primary lung infection, explains Prof Pohl-Albertyn.

Cryptococcus neoformans causes AIDS-defining illnesses in people living with HIV/AIDS. To the point, it was not surprising when the WHO declared it as the first critical fungal pathogen of concern. Dissemination to other organs has been reported where it crosses the epithelium barrier by secreting proteases (a class of enzymes that break down proteins in the host) that compromise the tight junctions between the epithelial cells.

The current projects investigate the interaction between the proteases secreted by C. neoformans and co-infecting viruses, such as SARS-CoV-2 and influenza. The SARS-CoV-2 virus is activated by proteases in the host and proteases also help the influenza virus to enter and infect the host cells. Since the host proteases are similar to those secreted by C. neoformans, these projects are focused on determining if the yeast proteases can also help the viruses to cause infection. This project is also extended to study Candida albicans proteases as this is also a common co-infecting yeast in COVID-19 patients (for more detail on C. albicans).

Another project looks at the application of plants as sources for novel drugs against C. neoformans. This is important since 75-80% of African and Asian populations still rely on traditional or complementary/alternative medicines for their primary health-care needs. Coupled to this, modern medicines have become increasingly expensive and thus inaccessible to many in developing countries. Moreover, there is a shift to more “organic” and “vegan” lifestyles as well as the use of herbal medicines to prevent or manage the development of certain diseases.

Yeast contaminated water

“Considering the severity of invasive fungal infection, it is important to study the dissemination and proliferation of various pathogenic or potentially pathogenic fungal species in our surrounding environments. It is crucial to identify major vectors that aid in the spread of pathogenic yeast to prevent infections in susceptible individuals, which mainly include immunocompromised or immunosuppressed individuals.

“Candida, Cryptococcus and Rhodotorula species are commonly found in a variety of water sources with which humans are in frequent contact through daily activities like bathing, washing of clothes and cooking. This recent information further warrants the investigation into the possibility that fungal infections may occur through contact with yeast contaminated water,” concludes Prof Pohl-Albertyn.

She says it is thus important to investigate the presence and antifungal susceptibility of yeast found in water as well as to identify ways to monitor potential fungal outbreaks, possibly through wastewater surveillance. The research aims to identify potentially pathogenic yeast species as well as to quantify levels of azole, specifically fluconazole, in wastewater. In addition, the fluconazole susceptibility of these isolates will be assessed in an attempt to link azole pollution of the environment to antifungal drug resistance development.

News Archive

Sarah, our own champion
2008-11-05

 
Sarah Shannon at the Paralympic Games in Beijing

 

Sarah Shannon, a second-year student in the Postgraduate Certificate in Education, has been involved in disability sport on national level for the past 12 years. Sarah has cerebral palsy.

In 1996 she participated at the South African National Championships for the physically disabled for the first time, entering for several sporting codes and winning five gold medals. In swimming she participates in the S3 class together with other swimmers that have comparable abilities to hers.

In 1997 she decided to focus on swimming competitively. She participated in her first national championships for swimming that year. After that (1998) she represented South Africa on international level at the International Paralympic Committee’s (IPC) Swimming World Championships in New Zealand where she ended 4th in the 50m backstroke and 7th in both the 50m and 100m freestyle in her class.

In 1999 she represented South Africa in Johannesburg at the 7th All Africa Games and won a silver medal for the 50m freestyle and a bronze medal for the 100m freestyle.

In 2000 she was part of the South African team at the Sydney Paralympic Games where she reached the finals and finished 7th in the 50m backstroke and 8th in the 50m freestyle. Northern-KwaZulu-Natal also awarded her the Junior Sportswoman of the Year award in 2001. In 2002 she participated at the South African Senior National swimming championships for KwaZulu-Natal in the multi-disability category.

In 2005 she completed the Midmar Mile. She also represented South Africa at the world championships for athletes with cerebral palsy in Boston in the United States of America. She won two gold medals for respectively the 50m freestyle and the 50m backstroke and two silver medals in the 100m and 200m freestyle. She was also nominated to represent South Africa as athlete’s representative on the world committee of CPISRA (Cerebral Palsy International Sports and Recreation Association). In this year Sarah also received the KwaZulu-Natal Premier’s Sportswoman with a disability award of the year.

In 2006 she qualified for the IPC world championships but could not attend.

In 2007 she represented South Africa once more at the Visa Paralympic World Cup in Manchester in the United Kingdom where she broke the South African record in the 50m backstroke, finishing 7th in the 50m freestyle and 6th in the 50m backstroke.

She was also part of the very successful Team South Africa to the Paralympic Games in Beijing. She reached the finals in both the 50m backstroke and 50m freestyle. She finished 7th in the 50m freestyle and 6th in the 50m backstroke in personal best times for both events. She has been participating in the able bodied South African National Swimming Championships since 2002. She is currently ranked 2nd in the world for short course items and 11th for the long course items. She is truly our best swimmer in the S3 class.
 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept